Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine (Q46640357)

23 December 2017

title

Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine (English)

1 reference

23 December 2017

0 references

0 references

Michael J Owens

1

1 reference

23 December 2017

Stan Krulewicz

2

1 reference

23 December 2017

Jeffrey S Simon

3

1 reference

23 December 2017

David V Sheehan

4

1 reference

23 December 2017

Michael E Thase

5

1 reference

23 December 2017

David J Carpenter

6

1 reference

23 December 2017

Susan J Plott

7

1 reference

23 December 2017

Charles B Nemeroff

8

1 reference

23 December 2017

language of work or name

English

0 references

publication date

16 April 2008

1 reference

23 December 2017

published in

Neuropsychopharmacology

1 reference

23 December 2017

volume

33

1 reference

23 December 2017

issue

13

1 reference

23 December 2017

page(s)

3201-3212

1 reference

23 December 2017

Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Effects of paroxetine and venlafaxine XR on heart rate variability in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Cerebrospinal fluid levels of amitriptyline, nortriptyline, imipramine and desmethylimipramine. Relationship to plasma levels and treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Imipramine and desipramine in plasma and spinal fluid: relationship to clinical response and serotonin metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

The burden of severe depression: a review of diagnostic challenges and treatment alternatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Treatment of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Pharmacological profile of antidepressants and related compounds at human monoamine transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Clinical efficacy of paroxetine in resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Inhibition of P-glycoprotein by newer antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

7 January 2021

Differential physiological effects of a low dose and high doses of venlafaxine in major depression

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

7 January 2021

Evidence of the dual mechanisms of action of venlafaxine

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

7 January 2021

Haloperidol plasma levels and clinical response in paranoid schizophrenics

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

7 January 2021

Synergistic benefits of serotonin and noradrenaline reuptake inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

7 January 2021

Paroxetine binding to the rat norepinephrine transporter in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

7 January 2021

Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

7 January 2021

Identifiers

DOI

10.1038/NPP.2008.47

1 reference

23 December 2017

1 reference

23 December 2017